Phase 1b norovirus challenge study is underway at Emory University School of MedicineCDI-988 is the first oral antiviral candidate being ...
Cocrystal Pharma, Inc. COCP shares are trading higher Thursday after the company announced that it has received Fast Track designation from the FDA for its CDI-988, the first oral antiviral candidate ...
Cocrystal specializes in antiviral therapies. It uses structure-based drug design—a platform that leverages computational chemistry and X-ray crystallography—to develop small molecule drugs targeting ...
BOTHELL, Wash., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces it has received a Small Business Innovation Research (SBIR) Phase I ...
Shares of Cocrystal Pharma, Inc. COCP are trading lower during Monday's pre-market session. The move follows a significant surge during the previous trading day. Nasdaq futures are up 0.43% while S&P ...
The latest price target for Cocrystal Pharma (NASDAQ:COCP) was reported by HC Wainwright & Co. on January 22, 2025. The analyst firm set a price target for $7.00 expecting COCP to rise to within 12 ...
$4.7 million upfront with up to an additional approximately $8.3 million of potential aggregate gross proceeds upon the exercise in full of warrants BOTHELL, Wash., Sept. 12, 2025 (GLOBE NEWSWIRE) -- ...
BOTHELL, Wash., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (COCP) (“Cocrystal” or the “Company”), announces the presentation of favorable data demonstrating activity of its potent ...
Patented and clinically verified nutraceutical actives outperform current branded offerings and offer a powerful solution for supplement product potency concerns. LAS VEGAS, Oct. 28, 2024 /PRNewswire/ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results